Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014))

Francois Mach; Colin Baigent; Alberico L. Catapano; Konstantinos C. Koskinas; Manuela Casula; Lina Badimon; M. John Chapman; Guy G. De Backer; Victoria Delgado; Brian A. Ference; Ian M. Graham; Alison Halliday; Ulf Landmesser; Borislava Mihaylova; Terje R. Pedersen; Gabriele Riccardi; Dimitrios J. Richter; Marc S. Sabatine; Marja Riitta Taskinen; Lale Tokgozoglu; Olov Wiklund; Djamaleddine Nibouche; Parounak H. Zelveian; Peter Siostrzonek; Ruslan Najafov; Philippe van de Borne; Belma Pojskic; Arman Postadzhiyan; Lambros Kypris; Jindřich Špinar; Mogens Lytken Larsen; Hesham Salah Eldin; Margus Viigimaa; Timo E. Strandberg; Jean Ferrieres; Rusudan Agladze; Ulrich Laufs; Loukianos Rallidis; Laszlo Bajnok; Thorbjorn Gudjonsson; Vincent Maher; Yaakov Henkin; Michele Massimo Gulizia; Aisulu Mussagaliyeva; Gani Bajraktari; Alina Kerimkulova; Gustavs Latkovskis; Omar Hamoui; Frank Visseren; Diederick Grobbee

doi:10.1016/j.atherosclerosis.2019.12.004

Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014))

Francois Mach^*
, Colin Baigent
, Alberico L. Catapano
, Konstantinos C. Koskinas
, Manuela Casula
, Lina Badimon
, M. John Chapman
, Guy G. De Backer
, Victoria Delgado
, Brian A. Ference
, Ian M. Graham
, Alison Halliday
, Ulf Landmesser
, Borislava Mihaylova
, Terje R. Pedersen
, Gabriele Riccardi
, Dimitrios J. Richter
, Marc S. Sabatine
, Marja Riitta Taskinen
, Lale Tokgozoglu

Olov Wiklund, Djamaleddine Nibouche, Parounak H. Zelveian, Peter Siostrzonek, Ruslan Najafov, Philippe van de Borne, Belma Pojskic, Arman Postadzhiyan, Lambros Kypris, Jindřich Špinar, Mogens Lytken Larsen, Hesham Salah Eldin, Margus Viigimaa, Timo E. Strandberg, Jean Ferrieres, Rusudan Agladze, Ulrich Laufs, Loukianos Rallidis, Laszlo Bajnok, Thorbjorn Gudjonsson, Vincent Maher, Yaakov Henkin, Michele Massimo Gulizia, Aisulu Mussagaliyeva, Gani Bajraktari, Alina Kerimkulova, Gustavs Latkovskis, Omar Hamoui, Frank Visseren, Diederick Grobbee, , ,

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Abstract

In row 4 of Table 3, ‘should’ should read as ‘may’; In 4.2.1, paragraph 3, ‘should’ should read ‘may’ to read ‘Overall, CAC score assessment with CT may be considered in individuals … ’ Also in the second row of ‘Recommendations for cardiovascular imaging for risk assessment of atherosclerotic cardiovascular disease,’ the Class should read ‘llb’; In the second paragraph of 7.5.2, ‘5–10 mg of monacolin K’ should read ‘2.5–10 mg’; and in the Key messages section, number 4, ‘ApoB may be a better measure of an individual's exposure to atherosclerotic lipoproteins' should read ‘ApoB may be a better measure of an individual's exposure to pro atherogenic lipoproteins'.

Original language	English
Pages (from-to)	80-82
Number of pages	3
Journal	Atherosclerosis
Volume	294
DOIs	https://doi.org/10.1016/j.atherosclerosis.2019.12.004
Publication status	Published - 1 Feb 2020

Keywords

guidelines
dyslipidaemia
cholesterol
triglycerides
low-density lipoproteins
high-density lipoproteins
apolipoprotein B
lipoprotein(a)
lipoprotein remnants
total cardiovascular risk
Treatment (lifestyle)
Treatment (drugs)
Treatment (adherence)
Very low-density lipoproteins
Familial hypercholesterolaemia

Access to Document

10.1016/j.atherosclerosis.2019.12.004

1-s2.0-S0021915019314595-mainFinal published version, 6.55 MBLicence: Taverne

Fingerprint

Dive into the research topics of 'Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014))'. Together they form a unique fingerprint.

2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk
The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC), 1 Jan 2020, In: European heart journal. 41, 1, p. 111-188 78 p.
Research output: Contribution to journal › Review article › peer-review

Open Access
File

Cite this

Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., Graham, I. M., Halliday, A., Landmesser, U., Mihaylova, B., Pedersen, T. R., Riccardi, G., Richter, D. J., Sabatine, M. S., Taskinen, M. R. (2020). Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014)). Atherosclerosis, 294, 80-82. https://doi.org/10.1016/j.atherosclerosis.2019.12.004

@article{1561868509bf457da64efdb4240e12ac,

title = "Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014))",

abstract = "In row 4 of Table 3, {\textquoteleft}should{\textquoteright} should read as {\textquoteleft}may{\textquoteright}; In 4.2.1, paragraph 3, {\textquoteleft}should{\textquoteright} should read {\textquoteleft}may{\textquoteright} to read {\textquoteleft}Overall, CAC score assessment with CT may be considered in individuals … {\textquoteright} Also in the second row of {\textquoteleft}Recommendations for cardiovascular imaging for risk assessment of atherosclerotic cardiovascular disease,{\textquoteright} the Class should read {\textquoteleft}llb{\textquoteright}; In the second paragraph of 7.5.2, {\textquoteleft}5–10 mg of monacolin K{\textquoteright} should read {\textquoteleft}2.5–10 mg{\textquoteright}; and in the Key messages section, number 4, {\textquoteleft}ApoB may be a better measure of an individual's exposure to atherosclerotic lipoproteins' should read {\textquoteleft}ApoB may be a better measure of an individual's exposure to pro atherogenic lipoproteins'.",

keywords = "guidelines, dyslipidaemia, cholesterol, triglycerides, low-density lipoproteins, high-density lipoproteins, apolipoprotein B, lipoprotein(a), lipoprotein remnants, total cardiovascular risk, Treatment (lifestyle), Treatment (drugs), Treatment (adherence), Very low-density lipoproteins, Familial hypercholesterolaemia",

author = "Francois Mach and Colin Baigent and Catapano, \{Alberico L.\} and Koskinas, \{Konstantinos C.\} and Manuela Casula and Lina Badimon and Chapman, \{M. John\} and \{De Backer\}, \{Guy G.\} and Victoria Delgado and Ference, \{Brian A.\} and Graham, \{Ian M.\} and Alison Halliday and Ulf Landmesser and Borislava Mihaylova and Pedersen, \{Terje R.\} and Gabriele Riccardi and Richter, \{Dimitrios J.\} and Sabatine, \{Marc S.\} and Taskinen, \{Marja Riitta\} and Lale Tokgozoglu and Olov Wiklund and Djamaleddine Nibouche and Zelveian, \{Parounak H.\} and Peter Siostrzonek and Ruslan Najafov and \{van de Borne\}, Philippe and Belma Pojskic and Arman Postadzhiyan and Lambros Kypris and Jind{\v r}ich {\v S}pinar and Larsen, \{Mogens Lytken\} and Eldin, \{Hesham Salah\} and Margus Viigimaa and Strandberg, \{Timo E.\} and Jean Ferrieres and Rusudan Agladze and Ulrich Laufs and Loukianos Rallidis and Laszlo Bajnok and Thorbjorn Gudjonsson and Vincent Maher and Yaakov Henkin and Gulizia, \{Michele Massimo\} and Aisulu Mussagaliyeva and Gani Bajraktari and Alina Kerimkulova and Gustavs Latkovskis and Omar Hamoui and Frank Visseren and Diederick Grobbee",

year = "2020",

month = feb,

day = "1",

doi = "10.1016/j.atherosclerosis.2019.12.004",

language = "English",

volume = "294",

pages = "80--82",

journal = "Atherosclerosis",

issn = "0021-9150",

publisher = "Elsevier Ireland Ltd",

}

Mach, F, Baigent, C, Catapano, AL, Koskinas, KC, Casula, M, Badimon, L, Chapman, MJ, De Backer, GG, Delgado, V, Ference, BA, Graham, IM, Halliday, A, Landmesser, U, Mihaylova, B, Pedersen, TR, Riccardi, G, Richter, DJ, Sabatine, MS, Taskinen, MR, Tokgozoglu, L, Wiklund, O, Nibouche, D, Zelveian, PH, Siostrzonek, P, Najafov, R, van de Borne, P, Pojskic, B, Postadzhiyan, A, Kypris, L, Špinar, J, Larsen, ML, Eldin, HS, Viigimaa, M, Strandberg, TE, Ferrieres, J, Agladze, R, Laufs, U, Rallidis, L, Bajnok, L, Gudjonsson, T, Maher, V, Henkin, Y, Gulizia, MM, Mussagaliyeva, A, Bajraktari, G, Kerimkulova, A, Latkovskis, G, Hamoui, O, Visseren, F , Grobbee, D 2020, 'Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014))', Atherosclerosis, vol. 294, pp. 80-82. https://doi.org/10.1016/j.atherosclerosis.2019.12.004

Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014)). / Mach, Francois; Baigent, Colin; Catapano, Alberico L. et al.
In: Atherosclerosis, Vol. 294, 01.02.2020, p. 80-82.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias

T2 - lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014))

AU - Mach, Francois

AU - Baigent, Colin

AU - Catapano, Alberico L.

AU - Koskinas, Konstantinos C.

AU - Casula, Manuela

AU - Badimon, Lina

AU - Chapman, M. John

AU - De Backer, Guy G.

AU - Delgado, Victoria

AU - Ference, Brian A.

AU - Graham, Ian M.

AU - Halliday, Alison

AU - Landmesser, Ulf

AU - Mihaylova, Borislava

AU - Pedersen, Terje R.

AU - Riccardi, Gabriele

AU - Richter, Dimitrios J.

AU - Sabatine, Marc S.

AU - Taskinen, Marja Riitta

AU - Tokgozoglu, Lale

AU - Wiklund, Olov

AU - Nibouche, Djamaleddine

AU - Zelveian, Parounak H.

AU - Siostrzonek, Peter

AU - Najafov, Ruslan

AU - van de Borne, Philippe

AU - Pojskic, Belma

AU - Postadzhiyan, Arman

AU - Kypris, Lambros

AU - Špinar, Jindřich

AU - Larsen, Mogens Lytken

AU - Eldin, Hesham Salah

AU - Viigimaa, Margus

AU - Strandberg, Timo E.

AU - Ferrieres, Jean

AU - Agladze, Rusudan

AU - Laufs, Ulrich

AU - Rallidis, Loukianos

AU - Bajnok, Laszlo

AU - Gudjonsson, Thorbjorn

AU - Maher, Vincent

AU - Henkin, Yaakov

AU - Gulizia, Michele Massimo

AU - Mussagaliyeva, Aisulu

AU - Bajraktari, Gani

AU - Kerimkulova, Alina

AU - Latkovskis, Gustavs

AU - Hamoui, Omar

AU - Visseren, Frank

AU - Grobbee, Diederick

PY - 2020/2/1

Y1 - 2020/2/1

N2 - In row 4 of Table 3, ‘should’ should read as ‘may’; In 4.2.1, paragraph 3, ‘should’ should read ‘may’ to read ‘Overall, CAC score assessment with CT may be considered in individuals … ’ Also in the second row of ‘Recommendations for cardiovascular imaging for risk assessment of atherosclerotic cardiovascular disease,’ the Class should read ‘llb’; In the second paragraph of 7.5.2, ‘5–10 mg of monacolin K’ should read ‘2.5–10 mg’; and in the Key messages section, number 4, ‘ApoB may be a better measure of an individual's exposure to atherosclerotic lipoproteins' should read ‘ApoB may be a better measure of an individual's exposure to pro atherogenic lipoproteins'.

AB - In row 4 of Table 3, ‘should’ should read as ‘may’; In 4.2.1, paragraph 3, ‘should’ should read ‘may’ to read ‘Overall, CAC score assessment with CT may be considered in individuals … ’ Also in the second row of ‘Recommendations for cardiovascular imaging for risk assessment of atherosclerotic cardiovascular disease,’ the Class should read ‘llb’; In the second paragraph of 7.5.2, ‘5–10 mg of monacolin K’ should read ‘2.5–10 mg’; and in the Key messages section, number 4, ‘ApoB may be a better measure of an individual's exposure to atherosclerotic lipoproteins' should read ‘ApoB may be a better measure of an individual's exposure to pro atherogenic lipoproteins'.

KW - guidelines

KW - dyslipidaemia

KW - cholesterol

KW - triglycerides

KW - low-density lipoproteins

KW - high-density lipoproteins

KW - apolipoprotein B

KW - lipoprotein(a)

KW - lipoprotein remnants

KW - total cardiovascular risk

KW - Treatment (lifestyle)

KW - Treatment (drugs)

KW - Treatment (adherence)

KW - Very low-density lipoproteins

KW - Familial hypercholesterolaemia

UR - https://www.scopus.com/pages/publications/85076858833

U2 - 10.1016/j.atherosclerosis.2019.12.004

DO - 10.1016/j.atherosclerosis.2019.12.004

M3 - Comment/Letter to the editor

AN - SCOPUS:85076858833

SN - 0021-9150

VL - 294

SP - 80

EP - 82

JO - Atherosclerosis

JF - Atherosclerosis

ER -

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al. Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014)). Atherosclerosis. 2020 Feb 1;294:80-82. doi: 10.1016/j.atherosclerosis.2019.12.004

Corrigendum to “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk” (Atherosclerosis (2019) 290 (140–205), (S0021915019314595), (10.1016/j.atherosclerosis.2019.08.014))

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Research output

2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk

Cite this